BMY News 50.51 04/21/2014 20:02:40 Bristol-Myers Squibb Company
Post# of 273249
Posted On: 04/21/2014 9:02:42 PM
Bristol-Myers Squibb Company (BMY) 50.51 $BMY
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - 2 hrs 32 mins ago
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
Final Glance: Pharmaceuticals companies
AP - 2 hrs 59 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Midday Glance: Pharmaceuticals companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Breaks Through Resistance at $49.78
Comtex SmarTrend(R) - Mon Apr 21, 11:44AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $49.36 today and has reached the first level of resistance at $49.78. Should the shares continue to rise, the resistance pivots of $50.09 and $50.82 will be of interest.
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Early Glance: Pharmaceuticals companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Would Pfizer Buying AstraZeneca Actually Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 9:03AM CDT
Mondays are commonly referred to as "Merger Mondays" for a reason: the weekend gives companies time to hash out deals without the overbearing scrutiny of Wall Street analysts and investors who are also off for the weekend. Although no such deal was...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - 2 hrs 32 mins ago
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
Final Glance: Pharmaceuticals companies
AP - 2 hrs 59 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Midday Glance: Pharmaceuticals companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb (BMY) Breaks Through Resistance at $49.78
Comtex SmarTrend(R) - Mon Apr 21, 11:44AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $49.36 today and has reached the first level of resistance at $49.78. Should the shares continue to rise, the resistance pivots of $50.09 and $50.82 will be of interest.
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Early Glance: Pharmaceuticals companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Would Pfizer Buying AstraZeneca Actually Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 9:03AM CDT
Mondays are commonly referred to as "Merger Mondays" for a reason: the weekend gives companies time to hash out deals without the overbearing scrutiny of Wall Street analysts and investors who are also off for the weekend. Although no such deal was...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences ' freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...
2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
(0)
(0)Scroll down for more posts ▼